Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/162663
Title: | Randomized Trial of Ceftazidime-Avibactam vs Meropenem for Treatment of Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia (REPROVE): Analyses per US FDA-Specified End Points |
Author: | Torres Martí, Antoni Rank, Doug Melnick, David Rekeda, Ludmyla Chen, Xiang Riccobene, Todd Critchley, Ian A. Lakkis, Hassan D. Taylor, Dianna Talley, Angela K. |
Keywords: | Pneumònia adquirida a la comunitat Microorganismes patògens Farmacologia Community-acquired pneumonia Pathogenic microorganisms Pharmacology |
Issue Date: | 25-Apr-2019 |
Publisher: | Oxford University Press |
Abstract: | Background: Hospital-acquired and ventilator-associated pneumonia (HAP/VAP; nosocomial pneumonia) due to Gram-negative pathogens are associated with significant morbidity and mortality; treatment options for multidrug-resistant infections are limited. The pivotal phase III REPROVE trial evaluated the efficacy of ceftazidime-avibactam (CAZ-AVI) vs meropenem in the treatment of patients with HAP/VAP. Study results for prespecified analyses per US Food and Drug Administration-recommended trial end points are reported here. Methods: Hospitalized adults with HAP/VAP proven or suspected to be caused by a Gram-negative pathogen were randomized 1:1 to receive CAZ-AVI or meropenem for 7 to 14 days. The primary outcome was 28-day all-cause mortality in the intent-to-treat (ITT) population. Secondary outcomes included clinical cure at test of cure (TOC) in the ITT and microbiological ITT (micro-ITT) populations, and safety and tolerability throughout the study. Results: hundred seventy randomized patients received treatment and were included in the ITT population (CAZ-AVI, n = 436; meropenem, n = 434). CAZ-AVI was noninferior to meropenem for the primary end point (28-day all-cause mortality; ITT) based on the prespecified 10% noninferiority margin (CAZ-AVI, 9.6%; meropenem, 8.3%; difference, 1.5%; 95% confidence interval [CI], -2.4% to 5.3%) and for the clinical cure end point in the ITT population based on a prespecified -10% noninferiority margin (CAZ-AVI, 67.2%; meropenem, 69.1%; difference, −1.9%; 95% CI, -8.1% to 4.3%). Clinical cure rates at TOC for patients infected with CAZ-nonsusceptible pathogens were similar (CAZ-AVI, 75.5%; meropenem, 71.2%; micro-ITT). Safety data were consistent with established safety profiles for both agents. Conclusions: CAZ-AVI provides an important new treatment option for HAP/VAP due to Gram-negative pathogens, including CAZ-nonsusceptible strains. |
Note: | Reproducció del document publicat a: https://doi.org/10.1093/ofid/ofz149 |
It is part of: | Open Forum Infectious Diseases, 2019, vol. 6, num. 4, p. 149 |
URI: | http://hdl.handle.net/2445/162663 |
Related resource: | https://doi.org/10.1093/ofid/ofz149 |
ISSN: | 2328-8957 |
Appears in Collections: | Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer) Articles publicats en revistes (Medicina) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
698269.pdf | 547.34 kB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License